Mirvetuximab Soravtansine (MIRV)

DRUG2 trials

Sponsors

AstraZeneca, NING LI-GYN

Conditions

Epithelial Ovarian CancerFallopian Tube CancersOvarian CancerPrimary Peritoneal Cancer

Phase 3

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

RecruitingNCT07218809

AstraZenecaEpithelial Ovarian Cancer

Start: 2025-12-29End: 2029-12-27Target: 1100Updated: 2026-07-21

Unknown Phase

A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα）

Not yet recruitingNCT07690332

NING LI-GYNOvarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer

Start: 2026-07-20End: 2028-09-30Target: 400Updated: 2026-07-24